

APPENDIX OF AMENDED CLAIMS

22. (Amended) The method of claim 21[0] wherein said adverse affect associated with microcompetition is cancer and said patient is being treated for cancer.
23. (Amended) The method of claim 21[0] wherein said adverse affect associated with microcompetition is atherosclerosis and said patient is being treated for atherosclerosis.
24. (Amended) The method of claim 21[0] wherein said adverse affect associated with microcompetition is osteoarthritis and said patient is being treated for osteoarthritis.
25. (Amended) The method of claim 21[0] wherein said adverse affect associated with microcompetition is obesity and said patient is being treated for obesity.
46. (Amended) A method of identifying compounds to be tested for treating adverse affects associated with a disruption of GABP's metabolic pathway, comprising:
- a) providing an assay capable of determining compounds that decrease[s] foreign DNA N-boxes in cells; and
 - b) running sample compounds through said assay and identifying any compound that performs one of said functions as a compound to be tested.